Investigating the Glucagon Receptor and Glucagon-Like Peptide 1 Receptor Activity of Oxyntomodulin-Like Analogues in Male Wistar Rats

Samantha L. Price, MRes, James S. Minnion, PhD, Stephen R. Bloom, MD*

Department of Investigative Medicine, Imperial College London, London, United Kingdom

ARTICLE INFO

Article history:
Accepted 24 October 2015

Key words:
analogue
body weight
glucagons
oxyntomodulin

ABSTRACT

Aims: To investigate the effect of Glu-3 OXM-like analogues on food intake and body weight in male rats.

Background: Oxyntomodulin (OXM) is a natural agonist at both the glucagon receptor (GCGr) and the glucagon-like peptide 1 receptor (GLP-1r), and peripheral administration reduces food intake and increases energy expenditure in rodents and humans. Substituting the native glutamine (Gln) at amino acid position 3 of OXM for glutamate (Glu) has previously been shown to diminish GCGr activity without affecting GLP-1r activity. The effects of Glu-3 OXM analogues have not been investigated in rats.

Methods: The effect of 2 Glu-3-substituted OXM-like analogues (eg, OXM14E3 and OXM15E3) on food intake and body weight was investigated in male Wistar rats during 6 days of daily subcutaneous (SC) administration. The effects of Glu-3 substitution on analogue binding and activity at the rat GCGr and rat GLP-1 receptor were investigated in vitro using Chinese hamster ovary or Chinese hamster lung cells.

Results: We report the novel finding that 2 5-nmol/kg Glu-3 OXM-like analogues (OXM14E3 and OXM15E3) significantly increased rat body weight by up to 4% compared with the equivalent non-Glu-3 analogues (OXM14 and OXM15), without affecting food intake. The effect of OXM15E3 on body weight was dose-dependent. Glu-3 analogues, including Glu-3 OXM, decreased glucagon-mediated cyclic adenosine monophosphate accumulation in Chinese hamster ovary cells expressing the rat GCGr, suggesting they may be acting as antagonists.

Conclusions: The results indicate Glu-3 OXM-like analogues might not be suitable tools to investigate the mechanism of OXM analogue action in a rat model because they significantly increase body weight independent of food intake. Glu-3 OXM analogues are partial agonists at the rat GCGr and may also act as antagonists, possibly resulting in the observed increase in body weight.

Introduction

The gut-derived hormone oxyntomodulin (OXM) is a naturally occurring dual agonist of both the glucagon receptor (GCGr) and glucagons-like peptide 1 receptor (GLP-1r).1 Structurally OXM is the 29 amino acids of glucagon with a C-terminal octapeptide tail.2 Administration of OXM to rodents and humans reduces food intake and increases energy expenditure, generating significant weight loss and highlighting OXM as a potential pharmacologic treatment for obesity.3,4 Due to the short in vivo half-life of native OXM, it is necessary to produce long-lasting analogues for clinical use.

The dual agonist properties of OXM make investigating its mechanism(s) of action difficult. Using GCGr or GLP-1r antagonists can interfere with the actions of endogenous glucagon and GLP-1, hormones that play critical roles in glucose homeostasis, giving an inaccurate picture of OXM actions. Alternatively, substituting glutamine at position 3 of OXM with Glu has previously been reported to diminish GCGr activity without affecting GLP-1r activity,6,7 enabling investigation of mechanisms of action relating to exogenous OXM administration.

These Glu-3 OXM analogues have been used in mice to investigate the contribution of GCGr and GLP-1r activity to the function of both native OXM7,8 and a derivatized analogue.6 Previous results indicate that OXM activity at the GLP-1r is responsible for the reduction in food intake and activity at the GCGr increases energy expenditure.6,7

Previous work in our lab designed OXM-like dual analogues of the GCGr and GLP-1r based on the 29 amino acids of glucagon.
A number of conservative amino acid substitutions were made to increase GLP-1r activity, improve peptide stability, and extended circulatory half-life, with a view to developing a potential treatment for obesity. Several equivalent Glu-3 analogues were also designed to investigate the contribution of GCGr and GLP-1r activity to the effects of the OXM-like dual analogues. Our pilot experiments suggested that Glu-3 OXM-like analogues increased body weight in rats without affecting food intake; therefore, further experiments were undertaken to clarify these findings. The 2 Glu-3 analogues OXM14E3 and OXM15E3 were chosen for investigation because they increased body weight in a pilot experiment and had similar conservative amino acid substitutions and pharmacokinetic profiles.

The results of our study suggest that Glu-3-substituted OXM analogues may be partial agonists that can act as competitive antagonists in vitro and increase body weight independent of food intake in vivo. Therefore Glu-3 OXM analogues are not a suitable tool to investigate the effects of OXM-like dual analogues in a rat model.

Methods

Compounds

All peptides (human glucagon, GLP-1, and OXM; analogues OXM14 and OXM15 and their respective Glu-3 analogues OXM14E3 and OXM15E3; and OXME3) were custom synthesized by Insight Biotechnology Limited (Middlesex, United Kingdom) and were >90% pure. The structure of analogues OXM14E3 and OXM15E3 were based on the 29 amino acids of glucagon and, other than the Glu-3 substitution, contained 6 single amino acid substitutions between residues 12 through 29. Both analogues had additional amino acids at residues 30 and 31 and OXM15E3 was C-terminally amidated (Figure 1). These analogues were chosen for investigation because they had similar pharmacokinetic profiles but different affinity and potency at the rat glucagon and GLP-1r.

Animals

Male Wistar rats (Charles River, Margate, United Kingdom) were maintained in individual cages under controlled temperature (21°C–23°C) and light conditions (12:12 light-dark cycle, lights on at 0700 hours) with ad libitum access to food (RM1 diet; SDS, Witham, United Kingdom) and water unless otherwise stated. All animal procedures were approved under the British Home Office Animals (Scientific Procedures) Act 1986 (Project Licence 70/7236).

In vivo food intake and body weight studies

Before study commencement, rats were randomized to treatment groups with equal mean body weights. An injection of peptide (maximum volume 50 μl, reconstituted in zinc chloride to enhance peptide depot formation9,10) or vehicle (saline) was administered subcutaneously at 1600 hours daily and food and body weight recorded.

Cell culture

All cell culture reagents were obtained from Invitrogen (Life Technologies Ltd, Paisley, United Kingdom) unless otherwise stated. Chinese hamster ovary-K1 cells overexpressing the rat GCGr were routinely maintained in Dulbecco’s modified eagle medium (DMEM) with 25 mM glucose and 1 mM sodium pyruvate supplemented with 10% fetal bovine serum, 25 mM hydroxyethyl piperazineethanesulfonic acid, 1% antibiotic (100 U/ml penicillin and 100 μg/ml streptomycin), and 1% nonessential amino acids. Chinese hamster lung cells overexpressing the rat GLP-1r were maintained in the same DMEM but without additional hydroxyethyl piperazineethanesulfonic acid or nonessential amino acids.

In vitro cyclic adenosine monophosphate (cAMP) accumulation

Levels of cAMP accumulation was measured in Chinese hamster ovary-K1 cells overexpressing the rat GCGr (cDNA from Origene, Cambridge Bioscience, Cambridge, United Kingdom) or Chinese hamster lung cells overexpressing the rat GLP-1r (a gift from Bernard Thorens, University of Lausanne, Switzerland).

Cells were seeded in a 48-well plate (Nunc, VWR International Inc, Chicago, Illinois) in their respective supplemented DMEM, at a density of 37,500 cells/well (250 μl/well), then incubated for 24 hours. Cells were serum starved in DMEM +1% antibiotic for 1 hour before 30 minutes’ incubation at room temperature with peptide concentrations diluted in serum-free DMEM with 1 mM IBMX (Sigma-Aldrich, Dorset, United Kingdom). Each peptide concentration was applied in duplicate or triplicate per experiment.

For rat GCGr antagonism studies, cells were incubated for 30 minutes with peptide concentrations diluted in serum-free DMEM with 1 mM IBMX and 0.1 nM glucagon. Five wells of each concentration and 12 wells of 0.1 nM glucagon alone were applied per experiment.

Postincubation, medium was removed and cells lysed with 120 μl/well of 0.1 M hydrochloride + 0.5% nonionic, octylphenol ethoxylate surfactant. cAMP levels were measured using an indirect ELISA according to the manufacturer’s instructions (ADI-900-066, Enzo Life Sciences, United Kingdom), optical density was read at 405 nm on a Biotek ELX808 (Wolf Laboratories, York, United Kingdom). Data were plotted and in vivo efficacy values calculated.

In vitro receptor binding: Supplementary

Refrer to O’Shea et al11 for detailed methods. Briefly, membranes were prepared from Chinese hamster ovary-K1 cells overexpressing the rat GCGr or Chinese hamster lung cells overexpressing the rat GLP-1r by osmotic lysis and differential centrifugation.

Figure 1. Schematic of the amino acid structures of the oxyntomodulin (OXM)-like dual analogues investigated in the study. Glu-3 = glutamate substitution at amino acid position 3.
Membranes (100 μg protein) were incubated in siliconized polypropylene tubes with 100 pm (500 Bq) either iodine125 labeled GLP-1 or iodine125 labeled glucagon in competition with unlabeled peptide. Total specific binding was calculated as the difference in counts between assays in the presence (nonspecific) and absence (total) of up to 6000 nM peptides. Data were plotted and in vitro affinity values calculated.

Statistical analysis

cAMP in vitro efficacy and binding in vitro affinity were calculated using nonlinear regression with Prism version 5 software (GraphPad Software Inc, San Diego, California). Differences in cumulative food intake and body weight were analyzed using 1-way ANOVA and post hoc tests with Dunnett or Bonferroni correction (Prism version 5 software). In all cases $P < 0.05$ was considered statistically significant.

Results

In vivo

Daily administration of 25 nmol/kg OXM14E3 to rats significantly increased body weight over 7 days (27.5 [2.2] g; $P < 0.01$) compared with vehicle controls (11.4 [2.6] g) and OXM14 (9.2 [3.8] g) (Figure 2B). Daily 25 nmol/kg OXM15E3 administration significantly increased body weight over 7 days (19 [3.3] g; $P < 0.01$) compared with OXM15 (4.5 [2.7] g) (Figure 2B). Food intake was not increased after administration of either OXM14E3 or OXM15E3 (Figure 2A).

Daily administration of 10 nmol/kg and 20 nmol/kg OXM15E3 resulted in a significant increase in rat body weight over 7 days (15.1 [1.9] g; $P < 0.05$ and 17.7 [1.5] g; $P < 0.01$, respectively) compared with vehicle controls (7.9 [2.0] g) (Figure 2D), without altering food intake (Figure 2C).

In vitro

At the rat GCGr the binding affinity of the Glu-3 substituted peptides OXM14E3 and OXM15E3 was 63-fold and 120-fold lower compared with OXM14 and OXM15, respectively (Figure 3D). Receptor binding affinity for the Glu-3 analogues at the rat GLP-1r was 2.7- to 4.4-fold greater than their Glu-3 counterparts (Figure 3D).

Substituting Glu at position 3 decreased peptide efficacy at the rat GCGr. The efficacy of OXM14E3, OXM15E3, and OXME3 was 200-, 25-, and 13-fold lower respectively compared with their Glu-3 equivalents OXM14, OXM15, and OXM. Glu-3 substitution increased rat GLP-1r efficacy by 1.2- to 1.6-fold (Figure 3D).

Concentrations of 0.03 to 1 nM OXM14E3 (Figure 3A) and 0.03 to 0.3 nM OXM15E3 (Figure 3B) decreased the percentage of glucagon-mediated cAMP production at the rat GCGr by a mean of 18.4% and 27.5%, respectively. Concentrations of 3 and 30 nM of OXM14E3 and OXM15E3 increased cAMP levels compared with glucagon stimulation alone (OXM14E3 30 nM: 155% increase, OXM15E3 30nM: 214% increase) (Figure 3A-B). Except 30 nM, all concentrations of OXME3 tested decreased glucagon-mediated cAMP accumulation by a mean of 40.3% (Figure 3C). A 30-nM

![Figure 2](image-url)

Figure 2. (A) Food intake and (B) body weight change after 7 days of daily subcutaneous (SC) 25 nmol/kg oxyntomodulin (OXM)14, OXM15, OXM14E3, OXM15E3, or vehicle (n = 6-7). (C) Food intake and (D) body weight change after 7 days of daily SC administration of various doses of OXM15E3 or vehicle (n = 11-12). Data are presented as mean (SEM). Statistical analysis was conducted using 1-way ANOVA and post hoc tests with Bonferroni (A and B) or Dunnett (C and D) corrections. *$P < 0.05$; **$P < 0.01$ versus vehicle controls; ***$P < 0.01$ versus peptide with native glutamine at amino acid position 3.
dose of OXME3 increased cAMP levels by 9% compared with glucagon stimulation alone (Figure 3C).

Discussion

Structurally, OXM is the 29 amino acids of glucagon with a C-terminal octapeptide tail. The dual agonist activity of OXM at the GCGr and GLP-1r makes it difficult to investigate the mechanisms involved in the weight-reducing effects of exogenous OXM administration because receptor antagonists also block the actions of endogenous glucagon and GLP-1. Previously it has been reported that exchanging the position-3 glutamine of OXM or a related analogue for Glu diminishes mouse GCGr activity without affecting activity at the mouse GLP-1 receptor. However, the Glu-3 OXM analogues may be partial agonists at the mouse and human GCGr binding affinity. Glucagon administration increases energy expenditure and in rodents this is postulated to be due to activation of brown adipose tissue. Exogenous peripheral administration of native OXM or long-acting analogues also increases energy expenditure and several murine studies have suggested a GCGr-mediated mechanism is responsible. Glu-3 OXM analogues may antagonize the activity of endogenous glucagon, possibly causing a reduction in energy expenditure and resulting in the observed increase in rat body weight. However endogenous glucagon has not been shown to play a tonic role in energy expenditure or weight regulation. Investigation of the effects of Glu-3 peptides on energy expenditure in rats is needed.

The present study reports the novel observation that substituting Glu at position 3 of 2 OXM-like dual analogues caused a significant increase in body weight in a rat model, without altering food intake. In line with previous findings at the mouse receptor, in vitro activity at the rat GCGr was diminished by Glu-3 substitution. Interestingly, glucagon-mediated activation of the rat GCGr in vitro was reduced by the lower concentrations of the Glu-3 analogues tested, including Glu-3 of native OXM. This suggests that the Glu-3 OXM analogues may be partial agonists that can also act as competitive antagonists in vitro, despite reduced rat GCGr binding affinity.

Glu-3 OXM analogues may antagonize the activity of endogenous glucagon, possibly causing a reduction in energy expenditure and resulting in the observed increase in rat body weight. However endogenous glucagon has not been shown to play a tonic role in energy expenditure or weight regulation. Investigation of the effects of Glu-3 peptides on energy expenditure in rats is needed.
with a proline substitution at amino acid position 3. Human GIP has several different residues compared with rat and mouse GIP, whereas the amino acid sequences of glucagon and OXM are identical in the 3 species. Therefore the relevance of the findings with Pro-3 GIP analogues to the present study is unclear.

Conclusions

OXM-like analogues with a Glu-3 substitution significantly increase body weight in a rat model, independent of food intake. Glu-3 analogues appear to be partial agonists at the rat GCGr and can also act as competitive antagonists in vitro. Therefore Glu-3 OXM-like analogues are unsuitable tools to investigate the effects of OXM analogue activity in a rat model.

Acknowledgments

The Section of Endocrinology and Investigative Medicine is funded by grants from the Medical Research Council (MRC), Biotechnology & Biological Sciences Research Council (BBSRC), National Institute for Health Research (NIHR), an Integrative Mammalian Biology Capacity Building Award, an FP7-HEALTH-2009-241592 European Obesity Consortium studying the Hypothalamus Interaction with Peripheral organs (EuroCHIP) grant, and is supported by the NIHR Biomedical Research Centre Funding Scheme. The views expressed are those of the author(s) and not necessarily those of the MRC, BBSRC or the NIHR.

All the authors were involved in writing and revising the manuscript.

S.L. Price designed and carried out experiments, conducted data analysis and wrote the manuscript. J.S. Minnion designed experiments and edited the manuscript. S.R. Bloom designed experiments and edited the manuscript.

Conflicts of Interest

The authors have indicated that they have no conflicts of interest regarding the content of this article.

References

1. Kerr BD, Flatt PR, Gault VA. D-Ser2)oxm[mpEG-PAL]: A novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions. Biochem Pharmacol. 2010;80:1727–1735.
2. Holst JJ. Enteroglucagon. Annu Rev Physiol. 1997;59:257–271.
3. Dakin CL, Small CJ, Batterham RL, et al. Peripherally oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology. 2004;145:2687–2695.
4. Wynne K, Park AJ, Small CJ, et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: A randomised controlled trial. Int J Obes (Lond). 2006;30:1729–1736.
5. Kervran A, Dubrasquet M, Blache P, Martinez J, Bataille D. Metabolic clearance rates of oxyntomodulin and glucagon in the rat: Contribution of the kidney. Regul Pept. 1990;31:41–52.
6. Pocai A, Carrington PE, Adams JR, et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes. 2009;58:2258–2266.
7. Kosinski JR, Hubert J, Carrington PE, et al. The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin. Obesity (Silver Spring). 2012;20:1566–1571.
8. Du X, Kosinski JR, Lao J, et al. Differential effects of oxyntomodulin and GLP-1 on glucose metabolism. Am J Physiol Endocrinol Metab. 2012;303:E265–E271.
9. Bartus RT, Tracy MA, Emerich DF, Zale SE. Sustained delivery of proteins for novel therapeutic agents. Science. 1998;281:1161–1162.
10. Ratner M, Nauck M, Kapitza C, Asnaghi V, Boldrin M, Balena R. Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: A randomized double-blind placebo-controlled study. Diabet Med. 2010;27:556–562.
11. O’Shea D, Morgan DGA, Meeran K, et al. Neuropeptide Y induced feeding in the rat is mediated by a novel receptor. Endocrinology. 1997;138:196–202.
12. Davidson IWF, Salter JM, Best CH. The effect of glucagon on the metabolic rate of rats. The American Journal of Clinical Nutrition. 1960;8:540–546.
13. Tan TM, Field BC, McCullough KA, et al. Co-administration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes. 2013;62:1131–1138.
14. Billington CJ, Briggs JR, Link JC, Levine AS. Glucagon in physiological concentrations stimulates brown fat thermogenesis in vivo. Am J Physiol. 1991;261:R501–R507.
15. Sparre-Ulrich AH, Hansen LS, Svendsen B, et al. Species-specific action of (Pro3) GIP 7 an efficacious agonist on human GIP receptor, but partial agonist and competitive antagonist on rat and mouse GIP receptors. Br J Pharmacol. 2015 September 11 Epub ahead of print.